EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and biological evaluation of furan‐bearing pyrazolo[3,4‐ b ]pyridines as novel inhibitors of CDK2 and P53–MDM2 protein–protein interaction

Manal Abdel Fattah Ezzat iD, Ghada F Elmasry iD, Menna M A Abd El-Mageed iD, Marwa A Fouad iD, Hatem A Abdel-Aziz iD, Safaa I Elewa iD

Drug Development Research · 2023

DOI: 10.1002/ddr.22079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Manal Abdel Fattah Ezzat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The novel series of furan‐bearing pyrazolo[3,4‐ b ]pyridines were designed as cyclin‐dependent kinase 2 (CDK2) inhibitors and as p53–murine double minute 2 (MDM2) inhibitors. The newly synthesized compounds were screened for their antiproliferative activity toward hepatocellular carcinoma (HepG2) and breast cancer (MCF7) cell lines. The most active compounds on both cell lines were additionally evaluated for their in vitro CDK2 inhibitory activity. Compounds 7b and 12f displayed enhanced activity (half‐maximal inhibitory concentration [IC 50 ] = 0.46 and 0.27 µM, respectively) in comparison to the standard roscovitine (IC 50 = 1.41 ± 0.03 µM), in addition to, cell cycle arrest at S phase and G1/S transition phase in MCF7 cells treated with both compounds, respectively. Moreover, the most active spiro‐oxindole derivative against MCF7 cell line, 16a , exhibited enhanced inhibitory activity against p53–MDM2 interaction in vitro (IC 50 = 3.09 ± 0.12 µM) compared to nutlin, and increased the levels of both p53 and p21 by nearly fourfold in comparison to the negative control. Molecular docking studies demonstrated the plausible interaction patterns of the most potent derivatives 17b and 12f in the CDK2 binding pocket and the spiro‐oxindole 16a with p53–MDM2 complex, respectively. Consequently, the new chemotypes 7b, 12f , and 16a can be presented as promising antitumor hits for further studies and optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Antineoplastic AgentsHumansAnimalsMiceCyclin-Dependent Kinase 2Molecular Docking SimulationProto-Oncogene Proteins c-mdm2PyridinesFuransCell ProliferationCell Line, TumorMolecular StructureDrug Screening Assays, AntitumorStructure-Activity Relationship

Stichwörter der Autor:innen

cyclin-dependent kinase 2furanmolecular dockingpyrazolo[3,4-b]pyridinestumor suppressor protein

Substanzen

Cyclin-Dependent Kinase 2Tumor Suppressor Protein p53Proto-Oncogene Proteins c-mdm2Antineoplastic AgentsPyridinesFuransCDK2 protein, humanMDM2 protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Pharmaceutical Chemistry Department, School of Pharmacy, NewGiza University, Cairo, Egypt.
  • Department of Applied Organic Chemistry, National Research Center, Giza, Egypt.
  • Organic Chemistry Department, Faculty of Women's for Arts, Science and Education, Ain Shams University, Cairo, Egypt.

ORCID-Profile: Manal Abdel Fattah Ezzat, Ghada F Elmasry, Menna M A Abd El-Mageed, Marwa A Fouad, Hatem A Abdel-Aziz, Safaa I Elewa

Zitieren

APA

Ezzat, M. A. F., Elmasry, G. F., El-Mageed, M. M. A. A., Fouad, M. A., Abdel-Aziz, H. A., & Elewa, S. I. (2023). Design, synthesis, and biological evaluation of furan‐bearing pyrazolo[3,4‐ b ]pyridines as novel inhibitors of CDK2 and P53–MDM2 protein–protein interaction. Drug Development Research. https://doi.org/10.1002/ddr.22079

Vancouver

Ezzat MAF, Elmasry GF, El-Mageed MMAA, Fouad MA, Abdel-Aziz HA, Elewa SI. Design, synthesis, and biological evaluation of furan‐bearing pyrazolo[3,4‐ b ]pyridines as novel inhibitors of CDK2 and P53–MDM2 protein–protein interaction. Drug Development Research. 2023. doi:10.1002/ddr.22079

BibTeX
@article{Ezzat2023,
  author = {Ezzat, Manal Abdel Fattah and Elmasry, Ghada F and El-Mageed, Menna M A Abd and Fouad, Marwa A and Abdel-Aziz, Hatem A and Elewa, Safaa I},
  title = {Design, synthesis, and biological evaluation of furan‐bearing pyrazolo[3,4‐ b ]pyridines as novel inhibitors of CDK2 and P53–MDM2 protein–protein interaction},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22079}
}
Kostenlos starten →